You can buy or sell PCRX and other stocks, options, ETFs, and crypto commission-free!
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Read More The company was founded in December 2006 and is headquartered in Parsippany, NJ.
Parsippany, New Jersey
52 Week High
52 Week Low
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Pacira Biosciences Inc.
Pacira Biosciences Inc NASDAQ/NGS:PCRX View full report here! Summary Bearish sentiment is low Economic output in this company's sector is expanding Bearish sentiment Short interest | Positive Short interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index ownership | Neutral E...
Yahoo FinanceMay 2
Pacira (PCRX) Misses Q1 Earnings Estimates
Lamb Weston (LW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Pacira (PCRX) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.33%. A quarter ago, it was expected that this specialty drugmaker would post earnings of ...
Expected Aug 1, Pre-Market